Standing Order
All companies

Biotech

Viking Therapeutics, Inc.

VKTXNASDAQpure-play
Market cap$3.2B
Conviction3/ 5
HQSan Diego, CA
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$24.77

-5.2%

Thesis

Viking Therapeutics is developing VK2735, a dual GLP-1/GIP receptor agonist, in both injectable and oral formulations. As a pure-play, its outlook is tied to the clinical progression of this metabolic candidate.

Catalysts

  • VK2735 injectable clinical trial readouts
  • VK2735 oral formulation data
  • Advancement into later-stage development

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 16
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07868939 (SUNRISE 2) of oral VK2735 for weight management in T2DM now recruiting.

  • Nov 16
    Trial initiationClinicalTrials.gov

    Phase 3 SUNRISE 1 trial (NCT07868835) of oral VK2735 for weight management updated to recruiting status.

  • Oct 28
    Financial resultsSEC

    VKTX 8-K (items 2.02, 9.01) reports results of operations.

  • Oct 16
    Trial initiationClinicalTrials.gov

    Phase 3 trial (SUNRISE 2) of oral VK2735 for weight management in Type 2 diabetes listed as not yet recruiting.

  • Oct 16
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07868835 (SUNRISE 1) for oral VK2735 weight management listed as not yet recruiting.

  • Oct 9
    Trial initiationClinicalTrials.gov

    Phase 3 trial (SUNRISE 1) of oral VK2735 for weight management listed as not yet recruiting.

  • Oct 9
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07868939 (SUNRISE 2) of oral VK2735 for weight management in T2DM updated to not yet recruiting.

  • Sep 29
    Trial initiationClinicalTrials.gov

    Viking Therapeutics initiates Phase 1 trial of VK3019 in overweight and obese adults (NCT07846033).

Not financial advice — research and opinion only. Disclosures